Reviewing Forty Seven Inc. (FTSV)’s and Bellerophon Therapeutics Inc. (NASDAQ:BLPH)’s results

We are contrasting Forty Seven Inc. (NASDAQ:FTSV) and Bellerophon Therapeutics Inc. (NASDAQ:BLPH) on their institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation. They both are Biotechnology companies, competing one another.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Forty Seven Inc. N/A 0.00 65.49M -2.06 0.00
Bellerophon Therapeutics Inc. N/A 0.00 2.81M -0.41 0.00

Table 1 shows the gross revenue, earnings per share (EPS) and valuation for Forty Seven Inc. and Bellerophon Therapeutics Inc.

Profitability

Table 2 provides the return on equity, return on assets and net margins of the two firms.

Net Margins Return on Equity Return on Assets
Forty Seven Inc. 0.00% 0% 0%
Bellerophon Therapeutics Inc. 0.00% 0% -64.8%

Liquidity

Forty Seven Inc. has a Current Ratio of 11.9 and a Quick Ratio of 11.9. Competitively, Bellerophon Therapeutics Inc.’s Current Ratio is 2.5 and has 2.5 Quick Ratio. Forty Seven Inc.’s better ability to pay short and long-term obligations than Bellerophon Therapeutics Inc.

Analyst Recommendations

Recommendations and Ratings for Forty Seven Inc. and Bellerophon Therapeutics Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Forty Seven Inc. 0 0 0 0.00
Bellerophon Therapeutics Inc. 0 0 1 3.00

Competitively Bellerophon Therapeutics Inc. has a consensus price target of $3, with potential upside of 334.78%.

Institutional & Insider Ownership

Forty Seven Inc. and Bellerophon Therapeutics Inc. has shares held by institutional investors as follows: 67.3% and 50.6%. About 5.1% of Forty Seven Inc.’s share are held by insiders. Comparatively, 7.8% are Bellerophon Therapeutics Inc.’s share held by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Forty Seven Inc. 1.35% 17.43% -6.15% 12.09% 0% 9.73%
Bellerophon Therapeutics Inc. -2.42% -8.49% -27.52% -20.98% -61.88% -19.14%

For the past year Forty Seven Inc. has 9.73% stronger performance while Bellerophon Therapeutics Inc. has -19.14% weaker performance.

Forty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; and FSI-189, an antibody that binds to SIRPa for the treatment of solid tumors. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices that address unmet medical needs in the treatment of cardiopulmonary diseases. Its product candidates are INOpulse, a pulsatile nitric oxide delivery device, which is in Phase III clinical trials for the treatment of pulmonary arterial hypertension; and in Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases and pulmonary hypertension associated with idiopathic pulmonary fibrosis. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.